The following is a summary of the Accuray Incorporated (ARAY) Q4 2024 Earnings Call Transcript:

Financial Performance:

• Accuray reported a Q4 revenue of $134 million, up 14% year-over-year.

• Full year revenue remained flat at $447 million, with product revenue contributing significantly to Q4 growth, up 28% year-over-year.

• Q4 adjusted EBITDA margins were within expected range, and gross margin for the quarter was reported at 28.6%, down from 31.9% the previous year primarily due to higher margin deferral and higher parts consumption in China.

Business Progress:

• Entering the Type B market in China with the final approval for the precision treatment planning system, enabling full system shipments and expected acceleration of majority shipments in Q2 FY '25.

• Achieved strong global orders growth, particularly in emerging markets like APAC and Latin America, with notable success in China growing orders by 80% year-over-year.

• Introduced several new products, including the CyberKnife system and the new Accuray Helix product, while continuing strategic partnerships to enhance service offerings.

Opportunities:

• Strong momentum and order growth in emerging markets, particularly with entry into the Type B market in China representing approximately $3 billion potential.

• Expansion into value segments of radiation therapy equipment, anticipating an extended period of top-line growth.

• Positive market response to recently approved products, including Tomo C in China and Accuray Helix in India, set to ship soon and expected to support future growth.

Risks:

• Slowdown in installation timelines impacting US market recovery, with revenues significantly down by 26% compared to the prior year.

• Global macroeconomic factors such as unfavorable foreign exchange and inflation impacting financial results despite operational efficiencies.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.